

MIRD DOSE ESTIMATE REPORT NO. 10

Radiation Absorbed Dose from Albumin Microspheres Labeled with Technetium-99m

Monte Blau, Robert Wicks, Stephen R. Thomas, and Katherine A. Lathrop

Task Group of the Medical Internal Radiation Dose Committee, The Society of Nuclear Medicine

J Nucl Med 23: 915-917, 1982

RADIOPHARMACEUTICAL

Human albumin microspheres,* pretreated with Sn²⁺, are labeled by the addition of [Tc-99m]pertechnetate. Over 95% of the particles are in the size range of 15-45 micrometers. The free pertechnetate in this preparation is less than 3%.

The kinetic behavior of the radioactivity from other lung-imaging agents (macroaggregated albumin, etc.), and from microspheres labeled with other nuclides or by other chemical techniques, may be quite different from that of the radiopharmaceutical described above. This report of dose estimates does not include information on these materials, or provide estimates for the dose from microspheres administered by other than the intravenous route.

NUCLEAR DATA

Technetium-99m decays to Tc-99 by isomeric transition, with a half-life of 6.02 hr. Technetium-99 decays by beta minus decay, with a half-life of 2.1×10^5 yr. The very small contribution of Tc-99 decay to the radiation dose has been ignored in these estimates. Decay data and radiation dose constants are listed in Table 1.

BIOLOGICAL DATA

The dose estimates in this report are based on distribution and excretion measurements on over 30 patients (1). Volunteers for this study came from the group of

patients referred to the Nuclear Medicine Clinic of the Buffalo Veterans Administration Medical Center for lung perfusion studies. All had normal lung scans. A detailed description of the technique used is given in Ref. 1. Measurements made at the University of Chicago and the University of Cincinnati support these data (personal communication, K. A. Lathrop and S. R. Thomas).

The initial uptake, as expected, is almost entirely in the lungs. The radioactivity apparently leaves the lungs in the form of TcO₄⁻, principally by leaching off the microspheres rather than by their breakup. This conclusion is based on the kinetic behavior of the Tc-99m activity after it leaves the lungs. The distribution of TcO₄⁻ following a single intravenous injection has been determined (2). However, radioactivity leaching from

TABLE 1. NUCLEAR DATA

Radionuclide	Tc-99m		
Physical half-life	6.02 h		
Mode of decay	I.T. to Tc-99		
$\Sigma\Delta_1$ for non-penetrating radiation	0.0332		
Principal photons	E_i	n_i	Δ_1
	18-21	0.074	0.0029
	140.5	0.89	0.266

E_i = energy (keV)

Δ_1 = mean energy emitted per unit cumulated activity (g-rad/ μ Cl-h)

n_i - mean number per transformation

Nonpenetrating radiation includes conversion and Auger electrons.

Data from NCRP Report #58 (5).

Received April 19, 1982; revision accepted June 9, 1982.

For reprints contact: Monte Blau, PhD, Dept. of Nucl. Med., State University of New York at Buffalo, 3495 Bailey Ave., Buffalo, NY 14215.

TABLE 2. PARAMETERS OF THE FRACTIONAL DISTRIBUTION FUNCTION, $\alpha_h(t)$, FOR Tc-99m FROM A SINGLE I.V. INJECTION OF LABELED MICROSPHERES

Source organ	$\alpha_h(t) = \alpha_{h_1}e^{-\lambda_1 t} + \alpha_{h_2}e^{-\lambda_2 t}$				$\tau(h)^\dagger$
	α_{h_1}	α_{h_2}	$\lambda_{j_1}(h^{-1})$	$\lambda_{j_2}(h^{-1})$	
Lung	0.600	0.413	0.383	0.0192	4.28
Stomach	-1.799	1.802	0.0886	0.0795	0.429
Kidney	-0.127	0.135	0.148	0.00204	0.672
Blood	-0.096	0.095	1.752	0.0363	0.580
Urine	-1.730	1.727	0.0331	0.0231	0.830
Bladder					0.209
Thyroid					0.020*
Salivary gland					0.041*
Large intestine					0.321*
Extra-vascular space					1.823*

* Calculated from lung disappearance curve and TcO_4^- kinetics. See text.

† Residence time, τ , includes physical decay ($\lambda = 0.115h^{-1}$) and is calculated as $\tau_n(\lambda) = \sum_j \alpha_{nj}/(\lambda + \lambda_j)$ (Eq. 32 of ref. 6); λ_j 's are biological rate constants only. Small discrepancies between tabulated τ 's and those calculated from the corresponding α 's and λ 's are due to rounding off of table entries.

the microspheres in the lungs enters the vascular space as the equivalent of a slow intravenous injection. The disappearance rate from the lungs as the input function was convolved with the equations in Ref. 2, which describe the kinetic behavior of TcO_4^- , to calculate the expected distribution of Tc-99m (3). When the TcO_4^- kinetic parameters given in Ref. 2 for "resting" subjects are used, the predicted blood and urine curves match those measured in the lung-study patients quite closely. In these patients the curve for radioactivity in the stomach was between those predicted from the kinetic parameters given in Ref. 2 for the "resting" group and for the "nonresting" group. Details are given in Ref. 1.

Table 2 lists the biologic parameters and residence times for the measured organs: lung, stomach, kidney, blood, and urine. In addition, derived residence times are given for thyroid, salivary gland, large intestine, and extravascular space, based on convolution integrals, calculated as described above, and using the biologic parameters given in Ref. 2 for "resting" subjects. The residence time for the bladder was calculated with a 4.8-hr emptying time, assuming an initially empty bladder. There was no measurable activity in the liver at any time.

The biologic parameters in Table 2 were derived from data obtained by conjugate counting using self-absorption corrections based on transmission images (1). The results have not been adjusted to 100% of the injected activity at each time period. Instead, the parameters listed are calculated from the directly measured values. The sum of the activities in the listed organs varied from 100-110% of the injected dose over the course of the study. Consequently, the sum of the calculated residence

times for the organs listed (excluding bladder, which is included in τ for urine) is 9.0 hr, although the theoretical maximum residence time for Tc-99m is 8.7 hr. Thus, the radiation absorbed doses calculated from these data are slight overestimates.

ABSORBED DOSE ESTIMATES

From the distribution data in Table 2 and the S values in MIRD pamphlet #11 (4), absorbed dose estimates were made for the organs listed as well as for red marrow, ovaries, and testes as target organs. In the absence of S values, the dose to salivary gland was not estimated. The doses to other organs from photons originating in the salivary gland was approximated by using the S values for thyroid as the source organ.

SUMMARY OF ESTIMATED ABSORBED DOSES AFTER I.V. ADMINISTRATION OF Tc-99m-LABELED MICROSPHERES

Organ	Dose per unit administered activity	
	rads/mCi	μ Gy/MBq
Lung	0.23	62.
Kidney	0.14	38.
Stomach	0.072	19.
Thyroid	0.072	19.
Bladder wall	0.040	11.
Large-intestine wall	0.035	9.4
Red marrow	0.020	5.4
Ovaries	0.013	3.5
Testes	0.005	1.4

FOOTNOTE

* 3M Corp.

ACKNOWLEDGMENT

The distribution studies, which serve as the basis for these dose estimates, were done under FDA Contract #223-78-6009.

REFERENCES

1. WICKS R, ROSENSPIRE K, ACKERHALT R, et al. Distribution of Tc-99m administered as labeled microspheres for lung imaging, in *Proceedings of 3rd International Radiopharmaceutical Dosimetry Symposium*. Watson EE, Schlafke-Stelson AT, Coffey JL, et al., Eds. Bureau of Rad. Health #FDA 81-8166, 1981, Washington, D.C., 454-463
2. LATHROP KA, ATKINS HL, BERMAN M, et al. Summary of current radiation dose estimates to normal humans from Tc-99m as sodium pertechnetate. *J Nucl Med* 17:74-77, 1976
3. BERMAN M: Kinetic models for absorbed dose calculations. *MIRD Pamphlet #12*, New York, The Society of Nuclear Medicine, 1977
4. SNYDER WS, FORD MR, WARNER GG, WATSON, SB: "S", absorbed dose per unit cumulated activity for selected radionuclides and organs. *MIRD Pamphlet #11*, New York, The Society of Nuclear Medicine, 1975
5. NCRP Report No. 58. A handbook of radioactivity measurements procedures. National Council on Radiation Protection and Measurements, Washington, D.C., 1978
6. LOEVINGER R, BERMAN M: A revised schema for calculating the absorbed dose from biologically distributed radionuclides. *MIRD Pamphlet #1, Revised*, New York, The Society of Nuclear Medicine, 1976

The Society of Nuclear Medicine 30th Annual Meeting

June 7-10, 1983

St. Louis, Missouri

Call for Abstracts for Scientific Program

The 1983 Scientific Program Committee solicits the submission of abstracts from members and nonmembers of the Society of Nuclear Medicine for the 30th Annual Meeting in St. Louis, MO. Abstracts accepted for the program will be published in the May issue of the *Journal of Nuclear Medicine*. Original contributions on a variety of topics related to nuclear medicine will be considered, including:

INSTRUMENTATION

COMPUTERS AND DATA ANALYSIS

IN VITRO RADIOASSAY

RADIOPHARMACEUTICAL CHEMISTRY

DOSIMETRY/RADIOBIOLOGY

NUCLEAR MAGNETIC RESONANCE

CLINICAL SCIENCE APPLICATIONS

Bone/Joint

Cardiovascular-Basic

Cardiovascular-Clinical

Correlation of Imaging Modalities

Gastroenterology

Hematology

Infectious Disease and Immunology

Neurology

Oncology

Pediatrics

Pulmonary

Renal/Electrolyte/Hypertension/Endocrine

Veterinary Nuclear Medicine

Only abstracts prepared on the official form will be considered. One official abstract form is required for each title submitted. Nine copies plus supporting data (three pages maximum) attached to each copy must accompany the official abstract form. To ensure that all those interested in submitting abstracts receive the form, a copy of the official abstract form was placed in the NOVEMBER issue of the JNM as a tear-out sheet. However, if you require additional forms, they may be obtained from the Society at the address below.

Abstracts of completed and on-going ("works in progress") projects will be judged together based on scientific merit.

Authors seeking publication for the full text of their papers are strongly encouraged to submit their work to the JNM for immediate review.

The official abstract form may be obtained from:

Society of Nuclear Medicine
Att: Abstracts
475 Park Avenue South
New York, NY 10016
Tel: (212)889-0717

Deadline for Receipt of Abstracts is Monday, January 17, 1983.